On hold programs

Commercial name Active substance Indication
Skyrizi Risankizumab treatment of patients with active Crohn's Disease who have no other suitable treatment option and are not eligible to participate in a clinical study for their serious or life-threatening condition.
Jemperli® dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.

 

 

Last updated on 28/09/2022